Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03116347
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 4
Start date May 30, 2017
Completion date January 15, 2021

See also
  Status Clinical Trial Phase
Completed NCT03277313 - Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects Phase 3
Completed NCT03716700 - Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
Active, not recruiting NCT05513586 - A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants Phase 3
Recruiting NCT05986734 - Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Completed NCT00546871 - Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects Phase 2/Phase 3
Recruiting NCT05755035 - A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases Phase 2/Phase 3
Completed NCT02593188 - Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Completed NCT00157079 - Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Phase 3
Completed NCT01412385 - Immune Globulin Subcutaenous (Human), 20% Phase 2/Phase 3
Completed NCT00161993 - Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Phase 2
Completed NCT01175213 - Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID Phase 3
Completed NCT01218438 - Phase 2/3 Study of IGSC, 20% in PIDD Phase 2/Phase 3
Completed NCT05150340 - A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) Phase 3
Not yet recruiting NCT06076642 - A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases Phase 3
Completed NCT00782106 - Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously Phase 1/Phase 2
Completed NCT01485796 - Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD Phase 2/Phase 3
Recruiting NCT06150534 - At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
Completed NCT00814320 - Gammagard Liquid and rHuPH20 in PID Phase 3
Completed NCT04346108 - A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) Phase 3